On July 29, AstraZeneca announced its results for the first half of 2025, achieving total revenue of $28.045 billion, an 11% year-on-year increase, including product revenue of $27.963 billion, an 11% year-on-year increase. By region, in the first half of the year, AstraZeneca's US market revenue reached $11.97 billion, a year-on-year increase of 12%, and its emerging market revenue reached $7.697 billion, a year-on-year increase of 12%. Revenue in China reached $3.515 billion, a year-on-year increase of 5%, accounting for over 12% of global revenue. "We are optimistic about China's innovation potential and will continue to expand our research and development presence in China," AstraZeneca disclosed. In March, the company announced a $2.5 billion investment plan in China, which included the establishment of its sixth global strategic research and development center in Beijing. Currently, two of AstraZeneca's six global strategic research and development centers are located in China.